Paweł Blecharz

ORIGINAL ARTICLE: Differences in the Soluble HLA-G Blood Serum Concentration Levels in Patients with Ovarian Cancer and Ovarian and Deep Endometriosis

Citation Mach P, Blecharz P, Basta P, Marianowski P, Skret‐Magierlo J, Kojs Z, Grabiec M, Wicherek L. Differences in the soluble HLA‐G blood serum concentration levels in patients with ovarian cancer and ovarian and deep endometriosis. Am J Reprod Immunol 2010

RCAS1 decidual immunoreactivity during stillbirth: immune cell presence and activity.

Problem  Alterations in RCAS1 (a receptor‐binding cancer antigen expressed on SiSo cells) expression in the placenta and decidua may be related to the regulation of the process of maternal immune tolerance against fetal antigens. Moreover, it has been demonstrated that the occurrence of the spontaneous beginning of stillbirth is related to a decrease in the placental expression of RCAS1. There are no data currently available on the immune processes in decidua during stillbirth. The aim of this study was to evaluate the RCAS1 immunoreactivity level in decidua and to identify the cytotoxic immune cells present during labor, induced after intrauterine fetal death either with a combination of oxytocin (OT) and prostaglandins or with OT alone; a further objective was to assess the potential impact of these molecular alterations on the effectiveness of stillbirth induction.

ORIGINAL ARTICLE: RCAS1 Decidual Immunoreactivity during Stillbirth: Immune Cell Presence and Activity

Problem  Alterations in RCAS1 (a receptor‐binding cancer antigen expressed on SiSo cells) expression in the placenta and decidua may be related to the regulation of the process of maternal immune tolerance against fetal antigens. Moreover, it has been demonstrated that the occurrence of the spontaneous beginning of stillbirth is related to a decrease in the placental expression of RCAS1. There are no data currently available on the immune processes in decidua during stillbirth. The aim of this study was to evaluate the RCAS1 immunoreactivity level in decidua and to identify the cytotoxic immune cells present during labor, induced after intrauterine fetal death either with a combination of oxytocin (OT) and prostaglandins or with OT alone; a further objective was to assess the potential impact of these molecular alterations on the effectiveness of stillbirth induction.

ORIGINAL ARTICLE: RCAS1 Decidual Immunoreactivity during Stillbirth: Immune Cell Presence and Activity: DECIDUAL RCAS1 AND STILLBIRTH

Problem  Alterations in RCAS1 (a receptor‐binding cancer antigen expressed on SiSo cells) expression in the placenta and decidua may be related to the regulation of the process of maternal immune tolerance against fetal antigens. Moreover, it has been demonstrated that the occurrence of the spontaneous beginning of stillbirth is related to a decrease in the placental expression of RCAS1. There are no data currently available on the immune processes in decidua during stillbirth. The aim of this study was to evaluate the RCAS1 immunoreactivity level in decidua and to identify the cytotoxic immune cells present during labor, induced after intrauterine fetal death either with a combination of oxytocin (OT) and prostaglandins or with OT alone; a further objective was to assess the potential impact of these molecular alterations on the effectiveness of stillbirth induction.

Metachronic cancers among women with brest cancer and BRCA1 mutation

Background: Breast cancer is the most common malignancy among women worldwide and in Poland. Mutation in BRCA1 gene is responsible for approximately 6% breast cancers in Poland diagnosed before the age of 50. BRCA1 dependent cancers occur early and frequently are bilateral. The purpose of this work was to evaluate the frequency of metachronic cancers in the population of 42 patients with breast cancer and BRCA1 mutation. Material and methods: Medical histories of 196 patients with confirmed mutation in BRCA1 gene consulted in the Krakow Branch of the Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology between 2005 and 2016 were analyzed. Medical histories of 42 patients with breast cancer were chosen for further analysis in the aspect of metachronic cancers. Results: During the observation period (mean of 10 years) 21 (50%) metachronic cancers were diagnosed, breast cancer was the most common one occurring in 16 (38%) cases. Additionally, 2 synchronic breast cancers occurred, and in 3 other cases breast cancer was the metachronic one. Conclusions: In light of the obtained results, the medical community should be aware of the scale of the problem of metachronic cancers among the patients with diagnosed BRCA1 mutation. Intensified surveillance for early detection of metachronic cancer and perspective of prophylactic mastectomy and adnexectomy for women treated from BRCA1 positive breast cancer should be considered.

Recommendations of the Polish Gynecological Oncology Society for the diagnosis andtreatment of endometrial cancer

© Medical Communications Sp. z o.o. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (CC BY-NC-ND). Reproduction is permitted for personal, educational, non-commercial use, provided that the original article is in whole, unmodified, and properly cited. Zalecenia Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka szyjki macicy Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of cervical cancer

Analysis of prognostic factors in vulvar cancer, with special emphasis on FIGO 2009 staging classification – results of own study and literature review

Sylwia Koryga-Wszołek1, Paweł Wojas2, Ewa Iwańska3, Maja Janeczek3, Kazimierz Karolewski3, Wiktor Szatkowski3, Paweł Blecharz3 Received: 16.03.2017 Accepted: 19.10.2017 Published: 30.11.2017

Treatment of advanced ovarian cancer with bevacizumab in Poland — a chance to improve survival still missed

In Poland the use of bevacizumab, angiogenesis inhibitor, in the treatment of patients with advanced ovarian cancer is financed by the Ministry of Health within the existing Drug Program. Available data indicate that not all patients who could benefit from such a treatment finally receive it. There could be many different reasons for this situation — some are due to patients’ clinical characteristics, but other result from misunderstanding of the eligibility criteria and the rules of the treatment program by physicians. The presented publication discusses comprehensively some oncological criteria that could be a subject of discussion, and which make qualification to bevacizumab-containing treatment more difficult.

ORIGINAL ARTICLE: Differences in the Soluble HLA-G Blood Serum Concentration Levels in Patients with Ovarian Cancer and Ovarian and Deep Endometriosis: DIFFERENCES IN SOLUBLE HLA-G BLOOD SERUM CONCENTRATION LEVELS

Citation Mach P, Blecharz P, Basta P, Marianowski P, Skret‐Magierlo J, Kojs Z, Grabiec M, Wicherek L. Differences in the soluble HLA‐G blood serum concentration levels in patients with ovarian cancer and ovarian and deep endometriosis. Am J Reprod Immunol 2010